Theodore Witek - Theseus Pharmaceuticals SVP
| THRXDelisted Stock | USD 4.06 0.00 0.00% |
SVP
Dr. Theodore J. Witek Jr. is Senior Vice President Corporationrationrate Partnerships Clinical and Medical Affairs of the Company. Theodore J. Witek Jr. Dr.P.H. joined Innoviva Inc. in July 2014. Prior to joining Innoviva Dr. Witek served as President and Chief Executive Officer of Boehringer Ingelheim in Canada and in Portugal. Joining Boehringer in 1992 Dr. Witek held a number of positions of increasing responsibility including leading the global clinical development and launch of several respiratory products most notably Spiriva. He also led the Respiratory and Immunology clinical research groups in the US in 2001 he moved to Germany to lead the operating team for Spiriva and also served as the Boehringer Cochair of the Joint Operating Committee with Pfizer in their global alliance. During his tenure in Canada Dr. Witek served on the Board of Directors at RxD Canada National Association for ResearchBased Pharmaceutical Companies chairing its Heath Technology Assessment and Public Affairs Committees. He also served over ten years on the DrugDevice Discovery and Development Committee of the American Thoracic Society serving as Chairman from 2010 to 2012. He is currently appointed to the Ontario Heath Innovation Council since 2014.
| Age | 57 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 857 400 9491 |
| Web | https://theseusrx.com |
Theseus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1789) % which means that it has lost $0.1789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2555) %, meaning that it created substantial loss on money invested by shareholders. Theseus Pharmaceuticals' management efficiency ratios could be used to measure how well Theseus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.98 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Theseus Pharmaceuticals has a current ratio of 26.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Theseus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Theseus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theseus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theseus to invest in growth at high rates of return. When we think about Theseus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Theseus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Theseus Pharmaceuticals (THRX) is traded on NASDAQ Exchange in USA and employs 38 people. Management Performance
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 |
Theseus Pharmaceuticals Leadership Team
Elected by the shareholders, the Theseus Pharmaceuticals' board of directors comprises two types of representatives: Theseus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theseus. The board's role is to monitor Theseus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Theseus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theseus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick LePore, Independent Director | ||
| DPhil DPHIL, CoFounder Chairman | ||
| Nachu Narasimhan, VP Safety | ||
| Theodore Witek, Sr. VP of Corporate Partnerships, Clinical and Medical Affairs | ||
| WeiSheng Huang, CoFounder Chemistry | ||
| Catherine Friedman, Independent Director | ||
| James Tyree, Independent Director | ||
| Terrence Kearney, Independent Director | ||
| Michael Faerm, Chief Bus. Officer and Sr. VP | ||
| Barbara Duncan, Independent Director | ||
| Paul Pepe, Independent Director | ||
| George Abercrombie, Senior Vice President - Corporate Partnerships, Commercial | ||
| Timothy Clackson, Pres CEO | ||
| Len Rozamus, VP Operations | ||
| Eric dEsparbes, CFO and Sr. VP | ||
| Bradford Dahms, Chief officer | ||
| Alicja Januszewicz, VP Culture | ||
| Victor Rivera, VP CoFounder | ||
| Benjamin Enerson, VP Affairs | ||
| Michael Aguiar, CEO and President and Director | ||
| Kristine CPA, VP Controller | ||
| William Waltrip, Lead Independent Director | ||
| MA DPHIL, CoFounder Chairman | ||
| David MD, Chief Officer | ||
| William Shakespeare, CoFounder RD |
Theseus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theseus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | (20.19 M) | |||
| Shares Outstanding | 44.65 M | |||
| Shares Owned By Insiders | 2.55 % | |||
| Shares Owned By Institutions | 93.28 % | |||
| Number Of Shares Shorted | 401.68 K | |||
| Price To Earning | 737.67 X | |||
| Price To Book | 0.81 X | |||
| EBITDA | (66.44 M) |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |